奥美拉唑在晚期非小细胞肺癌患者化疗中的疗效观察

目的观察奥美拉唑在晚期非小细胞肺癌患者化疗中的临床应用价值。方法将67例晚期非小细胞肺癌（Ⅳ期）患者按随机数字表法分为观察组（n=37）和对照组（n=30），2组均给予含铂两药联合化疗方案进行治疗。对照组在化疗第1天给予常规止吐药恩丹西酮、地塞米松、胃复安等；观察组在化疗第1天给予常规止吐药后，另给予奥美拉唑40mg静脉注射，开始每12h1次，1～2d后改为每日1次，用至化疗结束后1～2d。对2组患者出现的胃肠道反应和原始化疗方案疗程次数进行比较。结果观察组恶心、呕吐总有效率分别为89．2％、75．7％，对照组恶心、呕吐总有效率分别为66．7％、63．3％，2组比较差异均有统计学意义（均P〈0．05）。观察组原始化疗方案疗程次数多于对照组（P〈0．05）。结论奥美拉唑对化疗药物引起的胃肠道反应有一定的预防作用，对延缓化疗药物耐药可能有一定作用。

Clinical Efficacy of Omeprazole in Chemotherapy Patients with Non-small Cell Lung Cancer

Objective To observe the clinical application of omeprazole in chemotherapy patients with advanced non-small cell lung cancer（NSCLC）. Methods Sixty-seven patients with advanced NSCLC were randomly divided into two groups. All patients were treated with chemotherapy with combination of two platiniferous drugs. The control group（n=30） was given regular antiemetic drugs （ondansetrons, dexamethasone and metoelopramide, etc） on the first day of chemotherapy. The observation group（n= 37） was intravenously injected with 40 mg omeprazole （twice daily for 1-2 days and then once daily until 1-2 days after chemotherapy） after treatment with regular antiemetic drugs. Gastrointestinal reaction and the number of chemotherapy courses were compared between the two groups. Results The total effective rate was 89.2% for nausea and 75.7% for vomiting in observation group,and 66.7% for nausea and 63. 3% for vomiting in control group. The differences between the two groups were statistically significant （P〈0.05）. In addition, the number of chemotherapy courses in observation group was more than that in control group （P〈0.05）. Conclusion Omeprazole plays a role in preventing chemotherapy-induced gastrointestinal reaction and may have antitumor activity against chemotherapy-resistant NSCLC.